Hormone replacement therapy for postmenopausal osteoporosis

Clinics in Geriatric Medicine

Volumn 19, Issue 2, 2003, Pages 361-370

  Cranney, Ann ^a   Wells, George A ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLECALCIFEROL; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; CYTOKINE; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; INTERLEUKIN 1; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PARATHYROID HORMONE; PLACEBO; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR NECROSIS FACTOR; VITAMIN D;

ADULT; AGED; AGING; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FOOD AND DRUG ADMINISTRATION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; META ANALYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; THROMBOEMBOLISM; VERTEBRA FRACTURE;

AGED; BONE DENSITY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0037408381     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0690(02)00078-2     Document Type: Review

References (51)

1. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 2002;12:24-35.
2. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
3. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
4. American Association of Clinical Endocrinologists. 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 2001;7:293-311.
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
6. Riggs BL, Khosla S, Melton III LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both type 1 and type 2 osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763-73.
7. Pacifici R. Effect of surgical menopausal and estrogen replacment on cytokine release from human mononuclear cells. Proc Natl Acad Sci USA 1991;86:5136-8.
8. Cosman F, Shen V, Xie M, et al. A mechanism of estrogen action on the skeleton: production against the resorbing effects of (1-34) hPTH infusion as assessed by biochemical markers. Ann Intern Med 1993;118:337-43.
9. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fracture among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998;339:733-8.
10. NIH Consensus Development Panel - osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
11. Cauley JA, Zmuda JM, Ensrud KE, et al. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 2001;86:5700-5.
12. Wells G, Tugwell P, Shea B, et al. Meta-analysis of HRT for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23(4):529-39.
13. Lindsay R, Gallagher C, Kleerekoper M, et al. Effect of low doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-76.
14. Ensrud KE, Palermo L, Black DM, et al. Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures. J Bone Miner Res 1995;10:1778-87.
15. Quigley ME, Martin PL, et al. Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 1987;156:1516-23.
16. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group [see comments]. Arch Intern Med 1997;157:2609-15.
17. Recker RR, Davies KM, Dowd RM. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial. Ann Intern Med 1999;122:1141-6.
18. Villareal DT, Binder EF, Williams DB, et al. Bone mineral density response to estrogen replacement in frail women. A randomized controlled trial. JAMA 2001;286:815-20.
19. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA 1996;276:1389-96.
20. Speroff L, Rowan J, Symons J, et al. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 1996;276:1397-403.
21. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 1991;90:171-8.
22. Komulainen M, Tuppurainen MT, Kroger H, et al. HRT and Vitamin D in prevention of nonvertebral fractures in postmenopausal women: a 5-year randomized trial. Maturitas 1998;31:45-54.
23. Mosekilde L, Beck-Nielson H, Soresen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women: results of the Danish Osteoporosis Prevention Study. Maturitas 2000;36:181-93.
24. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy: a 10 year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979;53:277-81.
25. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-8.
26. Grady D, Cummings SR. Postmenopausal hormone therapy for prevention of fractures. JAMA 2001;285:2909-10.
27. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16.
28. Randell KM, Honkanen RJ, Kroger H, et al. Does hormone replacement therapy prevent fractures in early postmenopausal women? J Bone Miner Res 2002;17:528-33.
29. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS). JAMA 2002;288:49-57.
30. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
31. Humphrey LL, Chan BKS, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84.
32. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures. JAMA 2001;285:2891-7.
33. Herrington DM, Reboussin DM, Broshnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.
34. Ravn P, Bidstrup M, Wasnich RD. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four year results from the Early Postmenopausal Intervention Cohort Study. Ann Intern Med 1999;131:935-42.
35. Weiss SR, Ellman H, Dolker M. A randomized controlled trail of four doses of transdermal estradiol for preventing postmenopausal bone loss. Obstet Gynecol 1999;94:330-6.
36. Aitken JM, Hart DM, Lindsay R. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. BMJ 1993;3:515-8.
37. Cauley JA, Black DM, Barrett-Connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med 2001;110:442-50.
38. Alexandersen P, Riis BJ, Christiansen C. Monoflurophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in post-menopausal women: a randomized study. J Clin Endocrinol Metab 1999;84:3013-20.
39. Greenspan S, Bankhurst A, Bell N, et al. Effects of alendronate and estrogen alone and in combination on bone mass and turnover in postmenopausal osteoporosis. Bone 1998;23(5):S174.
40. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998;338:485-92.
41. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998;104:219-26.
42. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
43. Torgerson DJ, Bell-Syer SEM. Hormone replacment therapy and prevention of vertebral fractures. A meta-analysis of randomized trials. BMC Musculoskel Dis 2001;2:7-10.
44. Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy. Lancet 1981;1:459-61.
45. Eiken P, Nielsen SP, Kolthoff N. Effects on bone mass after eight years of hormonal replacement therapy. Br J Obstet Gynaecol 1997;104:702-7.
46. Greendale GA, Espeland M, Slone S, et al. Bone mass response to discontinuation of long-term hormone replacement therapy. Arch Intern Med 2002;162:665-72.
47. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
48. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboemobolic disease: the Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000;132:689-96.
49. Grodstein F, Mansori JE, Golditz FA, et al. A prospective study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41.
50. Miller J, Chan B, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US preventive services task force. Ann Intern Med 2002;136:680-90.
51. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.